[CAS NO. 150322-43-3] Prasugrel

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [150322-43-3]

Catalog

HY-15284

Brand

MCE

CAS

150322-43-3

DESCRIPTION [150322-43-3]

Overview

MDL	MFCD09954140
Molecular Weight	373.44
Molecular Formula	C20H20FNO3S
SMILES	FC1=CC=CC=C1C(C(C2CC2)=O)N3CCC4=C(C3)C=C(S4)OC(C)=O

For research use only. We do not sell to patients.

Summary

Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation ^[1] .

IC50 & Target

P2Y12 receptor ^[1]

In Vivo

In rat platelets, Prasugrel active metabolite inhibits in vitro platelet aggregation induced by adenosine ADP (10μM) with an IC ₅₀ value of 1.8 μM ^[2] .
Prasugrel acts faster and is significantly more potent than Clopidogrel in vivo. Prasugrel is an inactive prodrug that requires metabolic processing in vivo to generate the active antiplatelet metabolite. Prasugrel is rapidly absorbed from the gut. After oral administration of standard-loading doses of 60 mg, maximum plasma levels of the active metabolite are achieved within 1 h, effective, maximum inhibition of platelet aggregation at 1-2 h ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02285751	Medical University of Vienna	Critical Illness	November 2012	Phase 2
NCT00357968	Eli Lilly and Company\|Daiichi Sankyo, Inc.\|The TIMI Study Group	Coronary Artery Disease	August 2006	Phase 2
NCT01175200	Ascopharm Groupe Novasco\|Groupe Hospitalier Pitie-Salpetriere\|Medco Health Solutions, Inc.	Anti Platelet Effects	September 2010	Not Applicable
NCT02317198	St. Antonius Hospital\|UMC Utrecht\|Leiden University Medical Center\|Meander Medical Center\|Medical Center Alkmaar\|Isala\|Gelre Hospitals\|Gelderse Vallei Hospital\|Medical Centre Leeuwarden\|Rijnstate Hospital	Non-ST-elevation Acute Coronary Syndrome\|Unstable Angina\|Non-ST-elevation Myocardial Infarction	June 2013	Phase 4
NCT01765400	University of Nebraska\|Daiichi Sankyo, Inc.\|Eli Lilly and Company	Systolic Heart Failure	February 2013	Phase 4
NCT01777503	Arcispedale Santa Maria Nuova-IRCCS\|ANMCO Italian Association of Hospital Cardiologist\|Italian Society of Invasive Cardiology	Acute Coronary Syndrome\|Coronary Arteriosclerosis\|Myocardial Ischemia\|Cardiovascular Diseases	November 2012	Phase 4
NCT01648790	Eli Lilly and Company\|Daiichi Sankyo, Inc.	Healthy Volunteers	July 2012	Phase 1
NCT02545933	University of Florida\|Merck Sharp & Dohme LLC	Myocardial Infarction	February 2016	Phase 4
NCT02808767	Faculty Hospital Kralovske Vinohrady	Myocardial Infarction\|Angioplasty, Balloon, Coronary\|Platelet Aggregation Inhibitors	January 2013	Phase 4
NCT03027934	CirQuest Labs, LLC	Diabetes Mellitus	August 28, 2017	Phase 4
NCT00827411	Assistance Publique - Hôpitaux de Paris\|Allies in Cardiovascular Trials Initiatives and Organized\|Institut National de la Santé Et de la Recherche Médicale, France\|Sanofi\|Bristol-Myers Squibb\|Medtronic\|Cordis Corporation\|Fondation de France\|Diagnostica Stago\|Boston Scientific Corporation	Coronary Artery Disease\|Acute Coronary Syndrome	January 2009	Phase 4
NCT02422888	Amsterdam UMC, location VUmc\|Erasmus Medical Center\|Hospital San Carlos, Madrid\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|University Medical Center Nijmegen	Myocardial Infarction	May 2015	Phase 4
NCT01456364	Deutsches Herzzentrum Muenchen	Coronary Heart Disease	September 2011	Phase 4
NCT02487732	Korea University Anam Hospital\|AstraZeneca	Acute Coronary Syndrome	July 2015	Phase 4
NCT01015287	Eli Lilly and Company\|Daiichi Sankyo Co., Ltd.	Acute Coronary Syndromes	December 2009	Phase 3
NCT01790854	David Antoniucci\|A.R. CARD Onlus Foundation\|Careggi Hospital	Adverse Reaction to Antiplatelet Agent\|Acute Coronary Syndrome	November 2012	Phase 4
NCT03054207	Jules Desmeules\|University Hospital, Geneva	Hiv	June 2015	Phase 1
NCT00977938	Baim Institute for Clinical Research\|Abbott\|Boston Scientific Corporation\|Bristol-Myers Squibb\|Sanofi-Synthelabo\|Cordis Corporation\|Eli Lilly and Company\|Daiichi Sankyo, Inc.\|Medtronic	Coronary Artery Disease	October 2009	Phase 4
NCT00385944	Eli Lilly and Company\|Daiichi Sankyo, Inc.	Acute Coronary Syndrome	March 2007	Phase 2
NCT03430661	Idorsia Pharmaceuticals Ltd.	Healthy	January 24, 2018	Phase 1
NCT02065479	University of Florida	Coronary Artery Disease	March 2014	Phase 4
NCT01339026	Royal Brompton & Harefield NHS Foundation Trust\|University Hospital Tuebingen	Cardiovascular Disease\|Acute Coronary Syndrome	February 2012	Phase 4
NCT01327534	Stiftung Institut fuer Herzinfarktforschung\|Daiichi Sankyo, Inc.	Myocardial Infarction\|STEMI	May 2011	Phase 3
NCT01538446	Assistance Publique - Hôpitaux de Paris\|Eli Lilly and Company\|Daiichi Sankyo, Inc.\|Allies in Cardiovascular Trials Initiatives and Organized\|Accumetrics, Inc.\|Stentys	Acute Coronary Syndrome	March 2012	Phase 4
NCT00059215	Eli Lilly and Company	Cardiovascular Diseases\|Heart Diseases	April 2003	Phase 2
NCT01597375	Elliot Israel, MD\|Brigham and Women´s Hospital	Asthma, Aspirin-Induced\|Aspirin Exacerbated Asthma	August 31, 2012	Phase 2
NCT01641510	Dong-A University	Acute Coronary Syndromes	October 2013	Phase 3
NCT03016611	Sheba Medical Center	Acute Coronary Syndrome\|STEMI	February 2017	Phase 4
NCT02016170	University of Florida	Coronary Artery Disease\|Acute Coronary Syndrome	March 2014	Not Applicable
NCT01805570	David Antoniucci\|A.R. CARD Onlus Foundation\|Careggi Hospital	Myocardial Infarction	November 2012	Phase 4
NCT01493999	University of Pecs	Acute Coronary Syndrome	September 2011	Phase 4
NCT05086081	Brigham and Women´s Hospital	Acute Coronary Syndrome	October 10, 2020
NCT01107925	Eli Lilly and Company\|Daiichi Sankyo Co., Ltd.	Coronary Artery Disease	March 2010	Phase 1
NCT02507323	Yochai Birnbaum\|AstraZeneca\|Baylor College of Medicine	Cardiovascular Disease	February 2016	Phase 2
NCT01794000	Eli Lilly and Company\|Daiichi Sankyo, Inc.	Sickle Cell Disease	April 2013	Phase 3
NCT01109784	University of Patras	Coronary Artery Disease (CAD)\|Acute Coronary Syndrome (ACS)	April 2010	Phase 3
NCT00997503	Boston Scientific Corporation\|Eli Lilly and Company\|Daiichi Sankyo, Inc.	Coronary Artery Disease	December 2009
NCT04237922	Brigham and Women´s Hospital	Antiplatelet	September 22, 2019
NCT01360437	University of Patras	Coronary Artery Disease\|Acute Coronary Syndrome	May 2011	Phase 3
NCT01957540	University of Patras	Coronary Artery Disease\|Endothelial Function	June 2014	Phase 4
NCT01346800	University Hospital, Geneva	Healthy Volunteers	February 2011	Phase 1
NCT01560780	VA Office of Research and Development	Coronary Artery Bypass	February 1, 2013	Phase 3
NCT01452139	Ottawa Heart Institute Research Corporation\|Spartan Bioscience Inc.	STEMI	September 2011	Phase 2\|Phase 3
NCT01465828	Gennaro Sardella\|University of Roma La Sapienza	Acute Coronary Syndrome	October 2011	Phase 3
NCT01979445	The Medicines Company	Coronary Artery Disease (CAD)	December 2, 2013	Phase 2
NCT05223335	Mayo Clinic	Bleeding Complications	March 29, 2022	Phase 4
NCT04734353	Gyeongsang National University Hospital\|U&I Corporation	Coronary Artery Disease	January 15, 2020	Phase 4
NCT01505790	Assistance Publique Hopitaux De Marseille	Acute Coronary Syndromes	July 2011	Phase 3
NCT04668144	University of Florida\|Scott R. MacKenzie Foundation	Coronary Artery Disease\|Acute Coronary Syndrome	February 9, 2021	Phase 4
NCT01463163	University of Patras	Platelet Reactivity	October 2011	Phase 4
NCT05183178	Vastra Gotaland Region\|Region Skane\|Region Halland\|Region Gävleborg\|Region Örebro County\|Region Västerbotten\|Jämtland County Council, Sweden	Acute Coronary Syndrome	February 1, 2022	Phase 4
NCT01591317	Eli Lilly and Company	Healthy Volunteers	March 2009	Phase 1
NCT01959451	LMU Klinikum	Acute Coronary Syndrome	September 2013	Phase 4
NCT02944123	Dong-A University	Acute Coronary Syndrome	September 2016	Phase 3
NCT03469856	Pedro A. Lemos\|Imperial College London\|Cardialysis B.V.\|InCor Heart Institute	Monotherapy After PCI	February 22, 2018	Not Applicable
NCT00699998	Eli Lilly and Company\|Daiichi Sankyo Co., Ltd.\|Duke Clinical Research Institute	Acute Coronary Syndrome	June 2008	Phase 3
NCT01107899	Eli Lilly and Company\|Daiichi Sankyo Co., Ltd.	Acute Coronary Syndromes	October 2009	Phase 1
NCT01184300	Ottawa Heart Institute Research Corporation\|Spartan Bioscience Inc.	Stable Coronary Artery Disease\|Acute Coronary Syndrome\|Percutaneous Coronary Intervention	August 2010	Phase 2\|Phase 3
NCT01700322	Johannes Gutenberg University Mainz	Coronary Artery Disease	August 2012	Phase 4
NCT01642966	University of Patras	Acute Coronary Syndrome	September 2012	Phase 4
NCT02193971	Seoul National University Hospital\|Boston Scientific Korea Co. Ltd\|Dio\|Terumo Corporation\|Abbott	Acute Coronary Syndrome	July 2014	Phase 4
NCT01135667	Lene Holmvang\|Rigshospitalet, Denmark	Coronary Artery Disease\|Percutaneous Coronary Intervention\|Acute Coronary Syndromes	September 2010	Phase 4
NCT01106534	Abbott Medical Devices\|Baim Institute for Clinical Research\|Bristol-Myers Squibb\|Eli Lilly and Company\|Daiichi Sankyo, Inc.	Chronic Total Occlusion of Coronary Artery\|Vascular Disease\|Myocardial Ischemia\|Coronary Artery Stenosis\|Coronary Disease\|Coronary Artery Disease\|Coronary Restenosis	August 2009	Phase 4
NCT03489863	University of Florida\|Scott R. MacKenzie Foundation	Coronary Artery Disease	May 30, 2018	Phase 4
NCT01852214	University of Florida	Diabetes Mellitus\|Coronary Artery Disease	February 2013	Not Applicable
NCT01099566	Medical University of Vienna	Healthy Volunteers\|Sepsis	November 2009	Phase 4
NCT00954707	Cordis Corporation	Coronary Artery Disease	August 2009	Phase 4
NCT03273075	Medical University of Vienna	Cardiopulmonary Arrest With Successful Resuscitation\|ACS - Acute Coronary Syndrome\|Hypothermia, Induced	September 2017	Phase 4
NCT00642174	Eli Lilly and Company\|Daiichi Sankyo, Inc.	Diabetes Mellitus\|Coronary Artery Disease	April 2008	Phase 2
NCT05247385	University of Sao Paulo	Coronary Artery Disease	March 20, 2017	Phase 4
NCT01167023	Eli Lilly and Company\|Daiichi Sankyo, Inc.	Sickle Cell Anemia	July 2010	Phase 2
NCT03387826	Attikon Hospital	Myocardial Infarction\|Diabetes Mellitus\|Coronary Artery Disease\|Renal Disease	January 11, 2018	Phase 4
NCT01336348	Università degli Studi di Ferrara	ST Segment Elevation Myocardial Infarction	April 2010	Phase 3
NCT01830543	Janssen Scientific Affairs, LLC\|Bayer	Atrial Fibrillation\|Percutaneous Coronary Intervention	May 10, 2013	Phase 3
NCT05117866	Meditrix Corp\|Fujita Health University\|Boston Scientific Japan K.K.\|National University of Ireland, Galway, Ireland	Chronic Coronary Syndrome\|Non ST Segment Elevation Acute Coronary Syndrome	September 15, 2020	Not Applicable
NCT02548611	LMU Klinikum	Angina Pectoris	September 2015	Phase 4
NCT02261922	Hotel Dieu de France Hospital	Antiplatelet Agents; Endothelial Function; Pleotropic Effects	October 2014	Phase 4
NCT04981041	Ludwig-Maximilians - University of Munich	Acute Coronary Syndrome\|Atrial Fibrillation	December 16, 2021	Phase 4
NCT02587260	Erasmus Medical Center\|Covance	Cardiovascular Diseases	December 17, 2015	Phase 4
NCT01587651	Daiichi Sankyo, Inc.\|Eli Lilly and Company	Coronary Artery Disease	March 2012	Phase 4
NCT00910299	Eli Lilly and Company\|Daiichi Sankyo Co., Ltd.	Coronary Artery Disease (CAD)	July 2009	Phase 2
NCT00097591	Eli Lilly and Company\|Daiichi Sankyo, Inc.	Coronary Arteriosclerosis\|Acute Coronary Syndromes	November 2004	Phase 3
NCT01789814	Tufts Medical Center	Coronary Artery Disease	July 2013	Phase 4
NCT01852175	University of Florida	Coronary Artery Disease	January 2012	Not Applicable
NCT02075268	Asan Medical Center	Healthy	January 2014	Phase 1
NCT01598337	Prince Sultan Cardiac Center, Adult Cardiology Department.	Coronary Artery Disease	April 2011	Phase 3
NCT01612884	Indiana University	Thrombosis\|Coronary Artery Disease	August 2011	Phase 4
NCT01823185	Imam Abdulrahman Bin Faisal University\|King Fahad Armed Forces Hospital\|Dammam Central Hospital	Coronary Artery Disease\|Myocardial Infarction\|Heart Disease\|Vascular Disease\|Angina Pectoris\|Cardiovascular Disease\|Ischemia\|Infarction\|Embolism\|Thrombosis\|Chest Pain	March 2013	Phase 4
NCT01304472	University of Patras	Coronary Artery Disease (CAD)	February 2011	Phase 3
NCT01852019	The Medicines Company	Coronary Artery Disease	June 2013	Phase 2
NCT01944800	Deutsches Herzzentrum Muenchen\|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)	Acute Coronary Syndrome (ACS)	September 15, 2013	Phase 4
NCT03581409	Seoul National University Hospital\|Seoul National University Bundang Hospital	Aneurysm, Cerebral\|Endovascular Procedures	October 24, 2018	Phase 4
NCT01774838	University of Cologne	Acute Coronary Syndrome\|Unstable Angina	October 2014	Phase 3
NCT01155765	University of Patras	Hemodialysis\|Chronic Renal Failure	May 2010	Phase 3
NCT01178099	Eli Lilly and Company\|Daiichi Sankyo Co., Ltd.	Anemia, Sickle Cell	July 2010	Phase 1
NCT00356135	Eli Lilly and Company\|Daiichi Sankyo, Inc.	Coronary Arteriosclerosis\|Acute Coronary Syndrome	July 2006	Phase 2
NCT01510171	Careggi Hospital	ST-segment Elevation Myocardial Infarction	January 2012	Phase 4
NCT02212028	University of Florida	Coronary Artery Disease	October 2014	Phase 4
NCT01642940	University of Patras	Coronary Artery Disease\|Acute Coronary Syndrome	June 2012	Phase 4
NCT00830960	Eli Lilly and Company\|Daiichi Sankyo Co., Ltd.	Acute Coronary Syndrome	February 2009	Phase 3
NCT02070159	Dong-A University	Coronary Artery Disease	December 2011	Phase 3
NCT03454841	Collegium Medicum w Bydgoszczy	Acute Myocardial Infarction	February 26, 2018
NCT01365221	Medstar Health Research Institute	Acute Coronary Syndrome	October 2010	Phase 4
NCT02243137	David Vivas\|St Carlos Hospital, Madrid, Spain\|Fundacion Investigacion Interhospitalaria Cardiovascular	Adverse Effect of Antithrombotic Drugs	May 2013	Phase 1
NCT01201772	University of Florida	Coronary Artery Disease	August 2010	Phase 4
NCT01543932	University of Roma La Sapienza	Coronary Artery Disease	July 2012	Phase 3
NCT01463150	University of Patras	Platelet Reactivity	October 2011	Phase 4
NCT02075125	Dong-A University	ST-Segment Elevation Myocardial Infarction	January 2014	Phase 3
NCT01869309	LifeBridge Health\|AstraZeneca	Coronary Artery Disease	January 2014	Phase 4
NCT01835353	University of Patras	Platelet Reactivity	June 2012	Phase 3
NCT00976092	Deutsches Herzzentrum Muenchen	Myocardial Infarction	September 2009	Phase 4
NCT01531114	Gennaro Sardella\|University of Roma La Sapienza	ST-Elevation Myocardial Infarction	May 2013	Phase 3
NCT01338909	University of Patras	Myocardial Infarction	April 2011	Phase 3
NCT02866175	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company\|Daiichi Sankyo, Inc.	Atrial Fibrillation	February 24, 2017	Phase 3
NCT01260584	Daiichi Sankyo, Inc.	Coronary Artery Disease	November 2010	Phase 4
NCT04006288	University of Florida\|Janssen, LP	Coronary Artery Disease	September 6, 2019	Phase 4
NCT05491200	Research Maatschap Cardiologen Rotterdam Zuid\|Abbott Medical Devices	ST Elevated Myocardial Infarction\|Dual Antiplatelet Therapy	July 22, 2022	Phase 4
NCT01305369	University of Milan	Chronic Asthma	March 2011	Phase 4
NCT01452152	University of Maryland, Baltimore\|National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Acute Coronary Syndrome	February 2012	Phase 4
NCT02978040	University Hospital Inselspital, Berne	Coronary Artery Disease\|STEMI - ST Elevation Myocardial Infarction	July 4, 2017	Phase 4
NCT02108808	University of Patras	Fractional Flow Reserve	April 2014	Phase 4
NCT03672097	Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company\|Daiichi Sankyo, Inc.	Acute Coronary Syndrome (ACS)	October 16, 2018	Phase 4
NCT01014624	Daiichi Sankyo, Inc.	Coronary Artery Disease	February 2010	Phase 4
NCT01778842	Gennaro Sardella\|University of Roma La Sapienza	Coronary Artery Disease	March 2013	Phase 3
NCT01515345	Kaiser Franz Josef Hospital	Platelet Inhibition\|Coronary Stent Implantation	July 2011	Phase 3
NCT01476696	Eli Lilly and Company\|Daiichi Sankyo, Inc.	Sickle Cell Disease	November 2011	Phase 2
NCT03296540	Maasstad Hospital\|MicroPort Orthopedics Inc.\|Daiichi Sankyo, Inc.\|Research Maatschap Cardiologen Rotterdam Zuid	Cardiovascular Diseases	November 28, 2017	Phase 4
NCT03435133	AORTICA Group	ST Elevation Myocardial Infarction	November 23, 2015	Not Applicable
NCT01107912	Eli Lilly and Company\|Daiichi Sankyo Co., Ltd.	Coronary Artery Disease	March 2010	Phase 1
NCT01951001	Gyeongsang National University Hospital	Acute Coronary Syndrome\|Platelet Thrombus\|Bleeding	July 2013	Phase 4
NCT01430091	Eli Lilly and Company	Sickle Cell Disease	September 2011	Phase 1
NCT04445623	Azienda Ospedaliera Universitaria Integrata Verona\|University of Milan	COVID19\|Thrombosis	July 2020	Phase 3
NCT02215993	Federal University of São Paulo	Acute Coronary Syndrome\|Platelet Function	July 2013	Phase 4
NCT01609647	Dong-A University	Acute Coronary Syndrome	September 2012	Phase 3
NCT02376283	The Royal Wolverhampton Hospitals NHS Trust	Heart Attack	March 9, 2015	Phase 4
NCT05359224	Yonsei University\|Severance Hospital\|Gangnam Severance Hospital\|Bucheon St. Mary´s Hospital\|International St. Mary´s Hospital\|Ewha Woman´s University Seoul Hospital	Intracranial Aneurysm	June 13, 2022	Phase 4
NCT01115738	Eli Lilly and Company	Acute Coronary Syndrome	May 2010	Phase 2
NCT04766437	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Non ST Segment Elevation Acute Coronary Syndrome	February 19, 2021	Phase 2
NCT02032303	Azienda Policlinico Umberto I	Acute Coronary Syndrome\|Non ST Elevation Myocardial Infarction\|ST Elevation Myocardial Infarction\|Unstable Angina	February 2014	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 267.78 mM ; Need ultrasonic)

H ₂ O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6778 mL	13.3890 mL	26.7781 mL
5 mM	0.5356 mL	2.6778 mL	5.3556 mL
10 mM	0.2678 mL	1.3389 mL	2.6778 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.69 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.69 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.69 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-

Thieno[3,2-c]pyridine, ethanone deriv.

2-[2-(Acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)ethanone

CS 747

Prasugrel

2-Acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine

LY 640315

Effient free base

2-Acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno-[3,2-c]pyridine

[5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate